WE BELIEVE
the upper nasal space to be a gateway for improved absorption and hence, the potential for enhanced clinical outcomes.
The POD devices are designed to deliver a range of therapeutic molecules and formulations deep into the vascular-rich upper nasal space. This unique combination has the potential to deliver consistent and predictable doses of drug, potentially enabling on-demand access for molecules previously limited to injection and hospital-based use.
Indication
Preclinical
Phase 1
Phase 2
Phase 3
FDA Approved
Next anticipated milestone
Migraine
Acute Agitation and Aggression associated with ASD
Morning OFF Episodes in Parkinson’s